Analysts Offer Predictions for Cidara Therapeutics, Inc.’s Q3 2018 Earnings (CDTX)
Cidara Therapeutics, Inc. (NASDAQ:CDTX) – Equities researchers at Leerink Swann issued their Q3 2018 earnings estimates for shares of Cidara Therapeutics in a research note issued to investors on Thursday. Leerink Swann analyst P. Matteis anticipates that the biotechnology company will post earnings per share of ($0.72) for the quarter.
Cidara Therapeutics (NASDAQ:CDTX) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.21. ILLEGAL ACTIVITY NOTICE: This report was reported by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.dailypolitical.com/2017/11/12/analysts-offer-predictions-for-cidara-therapeutics-inc-s-q3-2018-earnings-cdtx.html.
A number of other brokerages also recently commented on CDTX. Cantor Fitzgerald set a $15.00 price objective on Cidara Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 10th. WBB Securities upgraded Cidara Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. Zacks Investment Research cut Cidara Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, August 14th. ValuEngine cut Cidara Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Finally, HC Wainwright lifted their target price on Cidara Therapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Cidara Therapeutics currently has an average rating of “Buy” and an average target price of $13.39.
Shares of Cidara Therapeutics (NASDAQ CDTX) opened at $7.80 on Friday. Cidara Therapeutics has a 52 week low of $5.60 and a 52 week high of $11.85. The company has a debt-to-equity ratio of 0.16, a current ratio of 7.69 and a quick ratio of 7.49.
A number of hedge funds have recently bought and sold shares of CDTX. Trexquant Investment LP bought a new position in Cidara Therapeutics during the second quarter worth about $110,000. Citadel Advisors LLC bought a new position in Cidara Therapeutics during the second quarter worth about $129,000. Raymond James Financial Services Advisors Inc. bought a new position in Cidara Therapeutics during the second quarter worth about $131,000. JPMorgan Chase & Co. lifted its holdings in Cidara Therapeutics by 455.6% during the first quarter. JPMorgan Chase & Co. now owns 25,639 shares of the biotechnology company’s stock worth $200,000 after acquiring an additional 21,024 shares in the last quarter. Finally, TIAA CREF Investment Management LLC lifted its holdings in Cidara Therapeutics by 4.9% during the first quarter. TIAA CREF Investment Management LLC now owns 39,065 shares of the biotechnology company’s stock worth $305,000 after acquiring an additional 1,840 shares in the last quarter. Hedge funds and other institutional investors own 66.11% of the company’s stock.
In related news, CEO Jeffrey Stein acquired 7,350 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The stock was acquired at an average cost of $6.79 per share, with a total value of $49,906.50. Following the completion of the purchase, the chief executive officer now directly owns 51,851 shares in the company, valued at $352,068.29. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 18.90% of the stock is owned by insiders.
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.
Receive News & Ratings for Cidara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.